Antagonism of Vaccine-Induced HIV-1-Specific CD4+ T Cells by Primary HIV-1 Infection: Potential Mechanism of Vaccine Failure

Journal of Immunology

Volumn 158, Issue 2, 1997, Pages 807-815

  Kent, Stephen J ^a,b   Greenberg, Philip D ^a   Hoffman, Mark C ^a   Akridge, Robert E ^a   McElrath, M Juliana ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL CLONE; CLASSIFICATION; CYTOTOXIC T LYMPHOCYTE; DRUG ANTAGONISM; EPITOPE MAPPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; PATHOGENICITY; VIROLOGY;

AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CLONE CELLS; EPITOPE MAPPING; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031567905     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Graham, B. S., and P. F. Wright. 1995. Candidate AIDS vaccines. N. Engl. J. Med. 333:1331.
2. McElrath, M. J., L. Corey, P. D. Greenberg, T. J. Matthews, D. C. Montefiori, L. Rowen, L. Hood, and J. I. Mullins. 1996. Human Immunodeficiency virus type-1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc. Natl. Acad. Sci. USA 93:3972.
3. Belshe, R., D. P. Bolognesi, M. L. Clements, L. Corey, R. Dolin, J. Mestecky, M. Mulligan, D. Stablein, and P. Wright. 1994. HIV infection in vaccinated volunteers. JAMA 272:431.
4. Kahn, J. O., K. S. Steimer, J. Baenziger, A. M. Duliege, M. Feinberg. T. Elbeik, M. Chesney, N. Murcar, D. Chernoff, and F. Sinangil. 1995. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J. Infect. Dis. 171:1343.
5. Li, C. R., P. D. Greenberg, M. J. Gilbert, J. M. Goodrich, and S. R. Riddell. 1994. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83: 1971.
6. Siliciano, R. F., R. C. Bollinger, K. M. Callahan, S. A. Hammond, A. Y. Liu, E. P. Miskovsky, J. F. Rowell, and P. E. Stanhope. 1992. Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients. AIDS Res. Hum. Retroviruses 8:1349.
7. + human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 248:1234.
8. + cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J. Infect. Dis. 168:92.
9. Johnson, R. P., S. A. Hammond, A. Trocha, R. F. Siliciano, and B. D. Walker. 1994. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lyrnphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J. Virol. 68:3145.
10. Koup, R. A. 1994. Virus escape from CTL recognition. J. Exp. Med. 180:779.
11. Evavold, B. D., and P. M. Allen. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 252:1308.
12. Alexander, J., J. Ruppert, K. Snoke, and A. Sette. 1994. TCR antagonism and T cell tolerance can be independently induced in a DR-restricted, hemagglutinin-specific T cell clone. Int. Immunol. 6:363.
13. Sloan-Lancaster, J., B. D. Evavold, and P. M. Allen. 1993. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363:156.
14. Racioppi, L., F. Ronchese, L. A. Matis, and R. N. Germain. 1993. Peptide-major histocompatibility complex class II complexes with mixed agaonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. J. Exp. Med. 177:1047.
15. Jameson, S. C., F. R. Carbone, and M. J. Bevan. 1993. Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells. J. Exp. Med. 177:1541.
16. Bertoletti, A., A. Sette, F. V. Chisari, A. Penna, M. Levrero, M. DeCarli, F. Fiaccadori, and C. Ferrari. 1994. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369:407.
17. Klenerman, P., S. Rowland-Jones, S. McAdam, J. Edwards, S. Daenke, D. Lalloo, B. Koppe, W. Rosenberg, D. Boyd, A. Edwards, P. Gianqvande, R. Phillips, and A. McMichael. 1994. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 369:403.
18. Couillin, I., F. Connan, P. B. Culmann, E. Gomard, J. G. Guillet, and J. Choppin. 1995. HLA-dependent variations in human immunodeficiency virus Nef protein alter peptide/HLA binding. Eur. J. Immunol. 25:728.
19. Meier, U.-C., P. Klenerman, P. Griffin, W. James, B. Koppe, B. Larder, A. McMichael, and R. Phillips. 1995. Cytotoxic T lymphocyte lysis inhibited by viable HIV mutants. Science 270:1360.
20. Cooney, E. L., A. C. Collier, P. D. Greenberg, R. W. Coombs, J. Zarling, D. E. Arditti, M. C. Hoffman, S. L. Hu, and L. Corey. 1991. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337:567.
21. Cooney, E. L., M. J. McElrath, L. Corey, S. L. Hu, A. C. Collier, D. Arditti, M. C. Hoffman, R. W. Coombs, G. E. Smith, and P. D. Greenberg. 1993. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl. Acad. Sci. USA 90:1882.
22. McElrath, M. J., L. Corey, D. Berger, M. C. Hoffman, S. Klucking, J. Dragavon, E. Petersen, and P. D. Greenberg. 1994. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. J. Infect. Dis. 169:41.
23. Mosier, D. E., R. J. Gulizia, P. D. MacIsaac, L. Corey, and P. D. Greenberg. 1993. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Proc. Natl. Acad. Sci. USA 90:2443.
24. Lieberman, J., J. A. Fabry, M. C. Kuo, P. Earl, B. Moss, and P. R. Skolnik. 1992. Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase. J. Immunol. 148:2738.
25. + cytotoxic T-lymphocyte clone that recognizes a conserved peptide sequence within the gp41 subunit of the envelope protein. Proc. Natl. Acad. Sci. USA 88:10277.
26. Earl, P. L., S. Koenig, and B. Moss. 1991. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J. Virol. 65:31.
27. +, HIV-SF2 Nef-specific T cells clones for antigen-processing and presentation requirements and for cytotoxic activity. Vaccine 12:885.
28. Belshe, R., M. L. Clements, R. Dolin, B. Graham, M. J. Elrath, G. J. Gorse, D. Schwartz, M. C. Keefer, P. Wright, L. Corey, D. P. Bolognesi, T. J. Matthews, D. M. Stablein, F. S. O'Brien, M. Eibl, F. Dorner, W. Koff, and the NIAID AIDS Vaccine Evaluation Group Network. 1993. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immundeficiency virus type 1 vaccine in subjects at low risk of infection. J. Infect. Dis. 168:1387.
29. Hammond, S. A., E. Obah, P. Shanhope, C. R. Monell, M. Strand, R. M. Robbins, W. B. Bias, R. W. Karr, S. Koenig, and R. F. Siliciano. 1991. Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells. J. Immunol. 146:1470.
30. Myers, G., B. Korber, K. T. Jeang, L. Henderson, S. Wain-Hobson, and G. N. Pavlakis, eds. 1994. Human Retroviruses and AIDS. 1994. Los Alamos, New Mexico: Theoretical Biology and Biophysics, Los Alamos National Laboratory.
31. Evavold, B. D., J. Sloan-Lancaster, and P. M. Allen. 1993. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol. Today. 14:602.
32. Evavold, B. D., L. J. Sloan, B. L. Hsu, and P. M. Allen. 1993. Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J. Immunol. 150:3131.
33. Haynes, B. F. 1993. Scientific and social issues of human immunodeficiency virus vaccine developments. Science 260:1279.
34. Graham, B. S., T. J. Matthews, R. B. Belshe, M. L. Clements, R. Dolin, P. F. Wright, G. J. Gorse, D. H. Schwartz, M. L. Clements, R Dolin, P. F. Wright, G. J. Gorse, D. Schwartz, M. C. Keefer, D. P. Bolognesi, L. Corey, D. M. Stablein, J. R. Esterlitz, S.-L. Hu, G. E. Smith, P. E. Fast, W. C. Koff, and the NIAID AIDS Vaccine Clinical Trials Network. 1993. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J. Infect. Dis. 167: 533.
35. Egan, M. A., W. A. Pavlat, J. Tartaglia, E. Paoletti E., K. J. Weinhold, M. L. Clements, and R. F. Siliciano. 1995. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HTV-1 MN env gene. J. Infect. Dis. 171:1623.